Search results
Showing 736 to 750 of 2208 results for guidelines
Interim methods guide for developing good practice guidance (PMG15)
This interim methods guide is based on the general principles and methods included in other methods guides for developing NICE guidance
Subcutaneous olanzapine for treating schizophrenia [TSID12289]
Topic prioritisation
Canagliflozin in combination therapy for treating type 2 diabetes (TA315)
Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes in adults.
Telmisartan–amlodipine–indapamide for untreated hypertension TS ID 12034
Topic prioritisation
In development Reference number: GID-QS10186 Expected publication date: TBC
Pre-hospital initiation of fluid replacement therapy in trauma (TA74)
Evidence-based recommendations on giving intravenous (IV) fluid replacement therapy for people with serious injuries before reaching hospital.
Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel (HTG320)
Evidence-based recommendations on faecal calprotectin tests for distinguishing between inflammatory bowel diseases (such as Crohn’s disease and ulcerative colitis) and non-inflammatory bowel diseases (such as irritable bowel syndrome).
Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.
Digital technologies to support asthma self-management: early value assessment
In development Reference number: GID-HTE10063 Expected publication date: 17 April 2026
Smoking: smoking status of people with bipolar, schizophrenia and other psychoses (IND154)
This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM124
Implanting a baroreceptor stimulation device for resistant hypertension
In development Reference number: GID-IP1180 Expected publication date: TBC
Complicated urinary tract infections: ceftolozane/tazobactam (ESNM74)
Summary of the evidence on ceftolozane/tazobactam for treating complicated urinary tract infections to inform local NHS planning and decision-making
Evidence-based recommendations on dabrafenib (Finlee) with trametinib (Spexotras) for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and over.